INCY

Business Context and Reporting Period

Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 1998
Business Overview: Incyte designs and markets genomic database products, software tools, and microarray-based gene expression services. In January 1998, the Company acquired Synteni, Inc., a microarray-based gene expression company, in a transaction accounted for as a pooling-of-interests. Consequently, all prior financial data presented in this filing have been restated to reflect the combined operations of Incyte and Synteni.

Key Financial Metrics

Note: Total liquid assets calculated as Cash ($32,944) + Restricted Cash ($4,000) + Marketable Securities ($93,766).

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 54% year-over-year for the three months ended June 30, 1998 ($33.1M vs. $21.4M) and 61% for the six-month period ($63.5M vs. $39.4M). Growth was driven by new and expanded database collaboration agreements.
• Profitability: Net income surged to $5.2M for the quarter and $8.8M for the six months, compared to $1.3M and $1.7M in the prior year periods. This improvement is attributed to revenue growth and increased interest income from higher cash balances.
• Expense Increases: Total costs and expenses rose to $28.8M (quarter) and $56.3M (six months). Research and Development (R&D) expenses increased significantly due to bioinformatics efforts and microarray production. Selling, General, and Administrative (SG&A) expenses rose due to marketing growth and legal fees related to the Affymetrix lawsuit.
• Acquisition Impact: The six-month 1998 results included a $1.2M acquisition-related charge for the Synteni merger. The Synteni acquisition also contributed to the restatement of 1997 comparative figures.
• Joint Venture Losses: The Company recorded a $0.6M loss from its joint venture, diaDexus, LLC, for the six months ended June 30, 1998. No such loss was recorded in the prior year period as the venture was formed in September 1997.

Guidance, Outlook, Risks, and Contingencies

• Litigation Risk: On January 6, 1998, Affymetrix, Inc. filed a lawsuit alleging willful infringement of U.S. Patent No. 5,445,934 regarding high-density arrays. Affymetrix seeks a permanent injunction and trebled damages. Incyte intends to defend vigorously, but the outcome is uncertain and could result in substantial expenses and diversion of management attention.
• Liquidity and Capital Resources: As of June 30, 1998, the Company held approximately $130.7M in cash, cash equivalents, and marketable securities. Management believes these resources are adequate to satisfy capital needs through at least June 1999. However, future funding may be required if revenue growth does not meet expectations or if capital expenditures for facilities and equipment increase.
• Profitability Uncertainty: While the Company has reported net income for the past six quarters, management cautions that there is no assurance of continued profitability. Significant fixed expenses related to database development and collaborator support may lead to operating losses if revenue targets are not met.
• Strategic Investments: The Company holds a 50% interest in diaDexus and has other equity investments (e.g., OncorMed, Oxford GlycoSciences). These investments may result in future losses or impairment charges. Specifically, OncorMed's auditors previously expressed doubt about its ability to continue as a going concern, though it was subsequently acquired by Gene Logic.
• Year 2000 Issue: The Company is evaluating the impact of the Year 2000 issue on its systems but does not currently expect the remediation costs to have a material impact on financial condition.

Investor Verification Checklist

• Restated Comparables: Verify that all 1997 comparative figures have been restated to include Synteni, Inc. operations due to the pooling-of-interests accounting treatment.
• Litigation Exposure: Monitor the status of the Affymetrix patent infringement lawsuit, as a negative outcome could result in injunctions, trebled damages, and significant legal costs.
• Revenue Concentration: Assess the dependency on database collaboration agreements, which constitute the primary revenue source, and the risk of non-renewal or early termination.
• Joint Venture Performance: Track the financial performance of diaDexus, LLC, as the Company records its share of losses, which impacted the six-month 1998 net income.
• Cash Burn vs. Runway: Confirm that the $130.7M in liquid assets remains sufficient to cover the projected increase in capital expenditures for the new 95,000 sq. ft. facility and ongoing R&D through 1999.